Alumis Inc
ALMS4.079USD
-0.051-1.24%
交易中 （美东）报价延迟15分钟
221.92M总市值
亏损市盈率 TTM
关于 Alumis Inc 公司
Alumis Inc. 是一家临床阶段的生物制药公司。该公司开发了两种酪氨酸激酶 2 (TYK2) 抑制剂：ESK-001，一种第二代抑制剂，该公司正在开发该抑制剂以最大限度地抑制靶标并优化耐受性，以及 A-005，一种中枢神经系统 (CNS) 渗透性分子。该公司建立了一系列分子，有可能作为单一疗法或联合疗法治疗一系列免疫介导疾病。ESK-001 是一种变构 TYK2 抑制剂，用于治疗斑块状银屑病、系统性红斑狼疮和葡萄膜炎。A-005 是一种 CNS 渗透性变构 TYK2 抑制剂，可在 CNS 内提供 TYK2 抑制的治疗益处，用于治疗一系列神经炎症和神经退行性疾病。该公司拥有多项早期发现资产，例如其数据分析平台确定的靶标，可用于治疗免疫介导的适应症。其数据分析证明了中枢神经系统疾病中 TYK2 抑制的遗传原理。
公司简介
公司代码ALMS
公司名称Alumis Inc
上市日期Jun 28, 2024
CEOMr. Martin Babler
员工数量168
证券类型Ordinary Share
年结日Jun 28
公司地址280 East Grand Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16502316625
网址https://www.alumis.com/
公司代码ALMS
上市日期Jun 28, 2024
CEOMr. Martin Babler
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
收入明细
FY2025Q1
暂无数据
地区USD
名称
营收
占比
United States
17.39M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月29日 周二
更新时间: 7月29日 周二
持股股东
股东类型
持股股东
持股股东
占比
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
持股股东
持股股东
占比
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
股东类型
持股股东
占比
Private Equity
34.50%
Venture Capital
7.06%
Investment Advisor
5.68%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
2.14%
Individual Investor
0.64%
Bank and Trust
0.43%
Research Firm
0.34%
Sovereign Wealth Fund
0.21%
Other
44.65%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
149
53.14M
55.36%
+11.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Foresite Capital Management, LLC
15.20M
15.83%
+5.22M
+52.25%
May 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.77%
+4.49M
+42.21%
May 21, 2025
Samsara BioCapital, LLC
4.80M
5%
+1.53M
+46.99%
May 21, 2025
VenBio Partners LLC
2.79M
2.9%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
2.15M
2.24%
--
--
Mar 31, 2025
SR One Capital Management, LP
1.96M
2.04%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.56M
1.63%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
1.48M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.35M
1.41%
+300.30K
+28.57%
Mar 31, 2025
The Vanguard Group, Inc.
937.20K
0.98%
+99.01K
+11.81%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Invesco Nasdaq Biotechnology ETF
占比0.03%
iShares Micro-Cap ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
iShares Biotechnology ETF
占比0.02%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Global X Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
